Researchers to Evaluate Use of Ion Mobility Mass Spectrometry for Tissue
Imaging for Cancer Research
MILFORD, Mass., Feb. 13 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) and Vanderbilt University Medical Center jointly announce collaborative research efforts using Waters(R) MALDI SYNAPT(TM) High Definition MS(TM) (HDMS(TM)) System for enhanced tissue imaging capabilities for oncology research within the University's Mass Spectrometry Research Center.
Researchers at the Vanderbilt University Medical Center are focused on novel mass spectrometry (MS) approaches to identify and visualize protein expression changes in cells as they transition from a healthy state through various stages of cancer.
"The goal of tissue imaging is to provide a window into the changes in the cellular proteome in disease," said Professor Richard Caprioli, Director of Mass Spectrometry Research Center at Vanderbilt University Medical Center. "We look forward to evaluating the use of ion mobility for enhanced MALDI imaging combined with high resolution, high sensitivity, orthogonal time-of-flight (Tof) mass spectrometry. Ultimately, we hope that enhanced tissue imaging techniques will provide data sets to be mined for diagnostic and prognostic information related to the various stages of cancer."
The SYNAPT HDMS system is the only commercial instrument to incorporate high efficiency ion mobility separation in a dual ionization mass spectrometer giving scientists maximum analytical power for discovery research challenges.
"This Vanderbilt University collaboration is the latest example of how
Waters works with leading researchers to push the limits of science," said
Brian Smith, Vice President, Mass
'/>"/>
| SOURCE Waters Corporation Copyright©2008 PR Newswire. All rights reserved |